Global survival and biochemical relapse-free survival in patients with prostate cancer treated with intensity modulated radiotherapy (IMRT) at the National Cancer Institute

Background: In 2018, prostate cancer ranked second in incidence worldwide. Advances in technology and the appearance of intensity-modulated radiotherapy, have made it possible to reduce doses to healthy tissue without reducing the coverage of the target volume, thus allowing lower morbidity associated with radiotherapy and the possibility of scaling the treatment dose. The aim of the study was to present the results in overall survival and biochemical relapse-free survival at the Colombian National Cancer Institute (INC) in patients diagnosed with non-metastatic prostate cancer treated with intensity-modulated radiotherapy (IMRT). Material and methods: The retrospective review included 98 patients over 40 years of age with prostate cancer, without evidence of metastatic disease, treated with IMRT between 2008 and 2015 irrespective of androgenic suppression. The administered dose of radiotherapy varied according to their risk based on the D.Amico classification. Results: The median age was 68.5 years, and of the total of 98 patients, 16 (16%) were classified as low risk, 33 (33%) as intermediate risk, and 49 (50%) as high risk. The mean dose of radiation therapy received was 75.8 Gy. Biochemical relapse-free survival at 5 years was 78.6%, and overall survival was 98%. Conclusions: In patients with high-risk prostate cancer, IMRT is an effective and safe alternative, with an overall 5-year survival of 98%, and an adequate dosimetric profile for at-risk organs.